Special Issue "Immune System Abnormalities Determining Recovery from Illness"

A special issue of BioMed (ISSN 2673-8430).

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 3987

Special Issue Editors

Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA
Interests: sepsis; outcome; recovery; epigenetic; post-ICU syndrome; extra-corporeal membrane oxygenation; immunoparalysis; anergy; behavioral economic; medical decision making; intensive care; medicine in austere settings
Special Issues, Collections and Topics in MDPI journals
Department of Neurology, University of Missouri, Columbia, MO, USA
Interests: traumatic brain injury, recovery, neuro0intensive care, stroke, innovation

Special Issue Information

The trajectory of the immune system response to acute illness determines the ability of individuals to recover. This initial response has short- and long-term consequences. The early immunological response is pivotal for the ability of patients to control invading pathogens or respond to insult, while the long-term response is pivotal to define extended recovery from illness. More and more appreciation is brought to the fact that the immune system does not function in only health and sick states, but several other characteristics are possible. The inherited disease of the immune system represents such abnormal states, but patients with autoimmune illnesses, on chemotherapy, immunosuppressed for transplantation purposes, or post-bone marrow or CART therapy are more prevalent examples of “atypical” immune system characteristics. Furthermore, patients surviving severe illnesses (trauma, sepsis, surgery, others) often suffer from acquired immune system abnormalities. Consequently, the immune system in a healthy patient is not a singular definition but a multidimensional construct.

This Special Issue of BioMed invites manuscripts (original work, reviews, case series) dealing with the immune system’s performance under “atypical” conditions, with special emphasis on the immune system as a determinant of recovery. Articles from the fields of autoimmune disease, critical care, COVID-19, transplant, and oncology are welcome. We will consider human, animal in silico, and clinical studies.

Dr. Krzysztof Laudanski
Dr. Cisco Francisco Gomez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioMed is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immune system
  • Homeostasis
  • Allostasis
  • Regulation
  • Performance
  • Recovery
  • Long term
  • Outcome
  • Atypical

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Case Report
Guillain–Barré Syndrome in COVID-19—The Potential Role of NCAM-1 and Immunotherapy
BioMed 2021, 1(1), 80-92; https://doi.org/10.3390/biomed1010006 - 15 Sep 2021
Cited by 2 | Viewed by 3192
Abstract
Coronavirus disease 2019 (COVID-19) interacts with the nervous system directly and indirectly by affecting the activation of the immune system. Guillain–Barré syndrome (GBS) is triggered by an inappropriate immune system activation that overlaps with the neurotoxic mechanism of an invading pathogen. Here, we [...] Read more.
Coronavirus disease 2019 (COVID-19) interacts with the nervous system directly and indirectly by affecting the activation of the immune system. Guillain–Barré syndrome (GBS) is triggered by an inappropriate immune system activation that overlaps with the neurotoxic mechanism of an invading pathogen. Here, we discuss the complexity of an abnormal immune system response leading to the generation of autoimmunity in the setting of acute viral infection. A 67-year-old male patient with COVID-19 developed a sensory motor acute polyneuropathy with respiratory failure. Several serum inflammatory and neurodegeneration markers were collected during hospital days 1, 3, 8, and 67 and compared to healthy individuals. Neural cell adhesion molecule 1 (NCAM-1) and neurofilament light chain (NfL) values were highly variable when compared to healthy individuals, but not to the reference COVID-19 group. We focused our attention on NCAM-1 as a possible target for antibodies directed at COVID-19 in silico. Full article
(This article belongs to the Special Issue Immune System Abnormalities Determining Recovery from Illness)
Show Figures

Figure 1

Back to TopTop